Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle

European Journal of Pharmacology

Volumn 150, Issue 1-2, 1988, Pages 85-94

  Silver, Paul J ^a   Hamel, Linda T ^a   Perrone, Mark H ^a   Bentley, Ross G ^a   Bushover, Cynthia R ^a   Evans, Dale B ^a  

^a EASTMAN KODAK COMPANY   (United States)

Author keywords

Cardiac muscle; Phosphodiesterase isozymes; Smooth muscle (tracheal); Smooth muscle (vascular)

Indexed keywords

4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; AMRINONE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; IMAZODAN; ISOENZYME; MILRINONE; PAPAVERINE; PIROXIMONE; ROLIPRAM; THEOPHYLLINE; ZAPRINAST;

ANIMAL CELL; ARTERY; DOG; DRUG SPECIFICITY; ENZYME INHIBITION; GUINEA PIG; HEART; NONHUMAN; PRIORITY JOURNAL; TRACHEA;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMAL; AORTA, THORACIC; CHROMATOGRAPHY, DEAE-CELLULOSE; DOGS; GUINEA PIGS; IN VITRO; ISOENZYMES; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM;

EID: 0023880662     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(88)90753-4     Document Type: Article

References (21)

1. Identification and properties of cyclic nucleotide phosphodiesterases
2. Modulation of cAMP: Mechanism for positive inotropic action
3. Cyclic nucleotides and regulation of vascular smooth muscle
4. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase. A receptor for new cardiotonic drugs
5. On the evaluation of the constants Vm and Km in enzyme reaction s
6. Specificity of cAMP phosphodiesterase inhibitors for subtypes of the type IV isoenzymes
7. Studies on the mechanism of the cardiotonic activity of MDL 19205: Effects on several biochemical systems
8. Regulation of adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate levels and contractility in bovine tracheal smooth muscle
9. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertability of major forms
10. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta
11. A weighted least squares computation of the Antoine constants from vapor pressure data using a microcomputer
12. Tissue specificity of cAMP-phosphodiesterase inhibitors
13. Inhibition of a high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscle
14. Effects of the cardiotonic/vasodilator agents amrinone and milrinore on phophodiesterase (PDE) isozymes and contractile force in guinea pig cardiac and vascular tissue
15. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme
16. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets: Isolation, characterization and effects of various reference phosphodiesterase inhibitors and cardiotonic agents
17. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity
18. Cyclic nucleotide phosphodiesterases
19. Selective inhibition of two soluble adenosine cyclic 3′,5′-phosphate phosphodiesterase partially purified from calf liver